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Abstract
Background Fibrosis of extracellular matrix (ECM) in
dilated cardiomyopathy (DCM) corresponds to the
myocardial over-production of various types of collagens.
However, mechanism of this process is poorly understood.
Objective To investigate whether enhanced metabolism of
ECM occur in DCM.
Methods Seventy consecutive DCM patients (pts)
(48 ± 12.1 years, EF 24.4 ± 7.4 %) and 20 healthy vol-
unteers were studied. Based on symptoms duration, pts
were divided into new-onset (n = 35, 6 months) and
chronic DCM (n = 35, [6 months). Markers of collagen
type I and III synthesis-procollagen type I carboxy- and
amino-terminal peptides (PICP and PINP) and procollagen
type III carboxy- and amino-terminal peptides (PIIICP and
PIIINP), collagen 1 (col-1), ECM metabolism controlling
factors—tumor growth factor beta-1 (TGF1-b), connective
tissue growth factor (CTGF), and ECM degradation
enzymes—matrix metalloproteinases (MMP-2, MMP-9)
and their tissue inhibitor (TIMP-1) were measured in
serum. All pts underwent right ventricular endomyocardial
biopsy to study ECM fibrosis.
Results The presence of fibrosis was detected in 24
(34.3 %) pts and was more prevalent in chronic DCM
[17 (48.6 %) vs. 7 (20 %), p\ 0.01]. The levels of
PIIINP [4.41 (2.17–6.08) vs. 3.32 (1.69–5.02) ng/ml,
p\ 0.001], CTGF [3.82 (0.48–23.87) vs. 2.37
(0.51–25.32) ng/ml, p\ 0.01], MMP-2 [6.06 (2.72–14.8)
vs. 4.43 (2.27–7.4) ng/ml, p\ 0.001], MMP-9 [1.98
(0.28–9.25) vs. 1.01 (0.29–3.59) ng/ml, p\ 0.002)], and
TIMP-1 [15.29 (1.8–36.17) vs. 2.61 (1.65–24.09) ng/ml,
p\ 0.004] were significantly higher in DCM, whereas
levels of col-1 [57.7 (23.1–233.4) vs. 159.4 (31.2–512.9)
pg/ml, p\ 0.001] were significantly lower in DCM
compared to controls. There were no differences in all
measured serum markers of ECM metabolism between
newonset and chronic DCM and as well as fibrosis
positive and negative pts. Fibrosis was weakly correlated
only with the duration of DCM (r = 0.23, p\ 0.05),
however, not a single serum marker of fibrosis correlated
with fibrosis. Neither unadjusted nor adjusted models,
constructed from serum markers of ECM metabolism,
predicted the probability of myocardial fibrosis.
Conclusions Dynamics of ECM turnover in DCM is high,
which is reflected by the increased levels CTGF and
degradation enzymes. Synthesis of collagen type III pre-
vailed over collagen type I. ECM metabolism was not
different in DCM regardless of the duration of the disease
and status of myocardial fibrosis. Serum markers of ECM
metabolism were found not to be useful for the prediction
of myocardial fibrosis in DCM.
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Introduction
The homeostasis of myocardial extracellular matrix (ECM)
involves an ongoing cycle of synthesis and degradation of
ECM components, mainly collagen, and is regulated by
multiple factors, including mechanical stretch, neuro-hor-
monal system, and growth factors and cytokines, such as
transforming growth factor beta (TGF-b) and connective
tissue growth factor (CTGF) [1]. In the healthy left ventricle
(LV) ECM replacement is about 5–9 %, however, in
pathological conditions, e.g., after myocardial infarction,
this figure can rise to 50 % [2]. ECM fibrosis is a hallmark of
dilated cardiomyopathy (DCM) and is a consequence of
collagen type I and III, which are major components of ECM,
overproduction and accumulation in the interstitium and
perivascular regions of the myocardium [3]. Synthesis of
collagen type I and III requires cleavage by respective
amino- and carboxy-terminal proteinases. As a result the
carboxy- and amino-terminal pro-peptides of procollagen
type I (PICP and PINP), and carboxy- and amino-terminal
pro-peptides of procollagen type III (PIIICP and PIIINP) are
released into the blood [4]. The appearance of those mole-
cules was observed after myocardial infarction, hypertrophic
cardiomyopathy, DCM or heart failure (HF) [5, 6].
Cardinal features of DCM, such as ventricular dilation and
impairment of systolic function, are partially caused by the
disintegration of collagenous network due to increased col-
lagen metabolism, e.g., degradation by collagenolytic activity
of matrix metalloproteinases (MMPs) and relative ineffi-
ciency of their tissue inhibitors (TIMPs) [7]. Elevated serum
concentrations of collagen pro-peptides, especially PICP and
PIIINP, have been associated with myocardial fibrosis and are
considered markers of increased collagen turnover [8].
Although ECM fibrosis is imprinted in DCM pathology,
still the process of fibrosis is not fully understood. Duration
of DCM seems to be the crucial factor in the fibrosis
development, however, paradoxically there are few studies
that unequivocally showed such a relationship. Measuring
blood markers of collagen metabolism indirectly provides
insight into fibrosis at the myocardial level.
We hypothesized that the magnitude and dynamics of
ECM fibrosis, assessed by means of blood markers, vary
between new-onset and chronic DCM as well as between
fibrosis positive and negative DCM.
Methods
Study group
From July 2014 to October 2015 we included 70 consec-
utive DCM patients who fulfilled pre-specified criteria and
were willing to participate in the study. DCM was diag-
nosed according to the current European Society of
Cardiology 2007 guidelines after an exclusion of signifi-
cant coronary artery disease, primary heart valve disease,
congenital heart disease, and arterial hypertension [9].
Based on detailed echocardiograms, all patients fulfilled
strict morphological and functional criteria, e.g., all had
dilated LV ([117 % of predicted LV end-diastolic diam-
eter according to the Henry formula) and significantly
depressed systolic function (LV ejection fraction \35 %)
[10, 11]. All patients had stable HF symptoms, according to
the New York Heart Association (NYHA) class I–III, for at
least last 2 weeks. Based on the duration of symptoms,
patients were divided into equal groups consisting of 35
subjects with new-onset (group 1, B6 months) and chronic
(group 2, [6 months) DCM presentation. Duration of HF
symptoms was defined as the time from the onset of sub-
jective symptoms (dyspnea on exertion or at rest,
paroxysmal nocturnal dyspnea, orthopnea, palpitations,
and/or edemas) to the index hospitalization or ambulatory
visit in cardiology clinics. Furthermore, the presence of
concomitant non-cardiac diseases, such as bone and joint
diseases, chronic liver insufficiency, peripheral
atherosclerosis, and neoplasms, affecting collagen meta-
bolism and the circulating levels of procollagens also
served as exclusion criteria. The study protocol was
approved by the relevant institutional committees and the
ethical committee. All patients gave a written informed
consent prior to the inclusion in the study.
Echocardiography
All measurements were performed according to the recent
recommendations of the European Associations of Car-
diovascular Imaging [12]. Examinations were performed
on commercially available equipment (Vivid 7 GE Medical
System, Horten, Norway) with a phased-array of
1.5–4 MHz transducer and tissue Doppler imaging (TDI)
software. The conventional M-mode, B-mode and Doppler
parameters, including LV ejection fraction (EF) were
calculated.
Invasive studies
Coronary angiography was performed in all patients to
exclude relevant coronary artery disease. Right heart
catherization (RHC) was performed according to practices
used at our center. Hemodynamic investigations were
evaluated with balloon-floating catheter and Siemens Inc.
Cathcor system. According to the Fick formula, cardiac
output and index were calculated. Based on standard for-
mulas, both systemic and pulmonary vascular resistance
were calculated.
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Endomyocardial biopsy (EMB)
EMB procedures were performed by experienced operators
via a femoral or jugular vein approach [13]. Long
(104 cm), flexible, disposable biopsy forceps seven French
size with small jaws (Cordis, Johnson & Johnson Co,
Miami Lakes, FL, USA) were used for the procedure.
According to the F Fr size, forceps can remove tissue
samples of *1.85 mm per 2.46 mm3. Simultaneous fluo-
roscopic guidance and bioptom curvature enabled the
precise biopsy of the right ventricular interventricular
septum. Up to five myocardial samples were obtained,
which were immediately stored in formalin (for light
microscopic examinations) or snap-frozen in OCT-
embedding medium and stored at -80 C for immuno-
histochemical or molecular studies. The presence of
fibrosis was determined qualitatively by an experienced
pathologist blinded to the clinical data.
Laboratory measurements
Venous blood samples were drawn on the day of the study
after a 30-min supine rest in a fasting state in the morning.
After centrifuge, supernatant was stored at -20 C until
assay. Concentration of collagen synthesis markers and
markers of collagen degradation were determined in
plasma using a commercially available ELISA tests as
follows: collagen type 1 (manufactures’ reference values
46.7–178.9 pg/ml), procollagen I N-terminal propeptide
(PINP 30.2–55.1 pg/ml), procollagen III N-terminal
propeptide (PIIINP 2.69–63.56 ng/ml), procollagen I
C-terminal propeptide (PICP 64–186 pg/ml =
0.064–0.186 ng/ml), procollagen III C-terminal propeptide
(PIIICP 5.2–35.5 ng/ml), connective tissue growth factor
(CTGF 2.3–42.5 ng/ml) (all from Cloud Clone Corp.
Houston, TX, USA); RayBio MMP2 ELISA (*400 ng/
ml), RayBio MMP9 ELISA (2.0–139.4 ng/ml), and Ray-
Bio TIMP-1 ELISA (up to 400 ng/ml) (all from
RayBiotech, Norcross, GA, USA) and TGF-b
(4.639–14.757 pg/ml = 4.639–14.757 ng/ml) (Diaclone
SAS, Besancon Cedex, France). All measurements were
performed by technicians blinded to the sample status.
Intra-assay and inter-assay coefficients of variation
were\7 %.
Control group
We included 20 healthy individuals (age 35.8 ± 7.9 years,
LV end-diastolic diameter 49.3 ± 3.4 mm, ejection frac-
tion 63.8 ± 4.7 %) who volunteered to become the control
group. The display of the control group serum markers of
fibrosis results and manufactures’ reference values is dis-
played in the table below.
Parameter Healthy controls
(n = 20)
Manufactures’
reference values
PICP (ng/ml) 0.23 (0.06–0.32) 0.064–0.186
PINP (pg/ml) 129.9 (75.6–448.1) 30.2–55.1
PIIICP (pg/ml) 187.2 (88.1–390.3) 5.2–35.5
PIIINP (ng/ml) 3.32 (1.69–5.02) 2.69–63.56
Col-1 (pg/ml) 159.4 (31.2–512.9) 46.7–178.9
TGF-b1 (ng/ml) 2.22 (0.97–4.74) 4.639–14.757
CTGF (ng/ml) 2.37 (0.51–25.32) 2.3–42.5
MMP-2 (ng/ml) 4.43 (2.27–7.4) Up to 400
MMP-9 (ng/ml) 1.01 (0.29–3.59) 2.0–139.4
TIMP-1 (ng/ml) 2.61 (1.65–24.09) Up to 400
Statistical analysis
Distribution of variables was assessed with Shapiro–Wilk
test. Comparisons of clinical parameters in groups were
conducted with t Student test or with Mann–Whitney tests
if lack of normality was found in. The same applies to
comparison between fibrosis and no-fibrosis groups. Four
groups of patients (new-onset DCM with or without
fibrosis and chronic DCM with or without fibrosis) were
compared using Kruskal–Wallis test, since again lack of
normality was found in Shapiro–Wilk test. Impact of
selected parameters on fibrosis probability was analyzed in
logistic regression method. Three models were analyzed:
unadjusted model, model with adjustment to disease
duration and model with adjustment to disease duration,
age, sex and BMI.
Results
Patients characteristics
Table 1 shows the baseline characteristics assessed in the
two groups of patients with early (group 1, n = 35,
B6 months) and chronic DCM (group 2, n = 35,
[6 months). Early DCM patients had significantly smaller
LV end-systolic diameter, measured in the parasternal long
axis view, however, LV wall thickness, LV volumes, EF,
and E/E’ were similar in both groups. The presence of
fibrosis was detected in 24 (34.3 %) pts and was signifi-
cantly more prevalent in chronic DCM. Pulmonary artery
(PA) pressure and the presence of secondary pulmonary
hypertension (PH) were comparable between two groups.
Similarly, peak oxygen uptake (VO2peak) during car-
diopulmonary exercise test was not different between
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groups. Patients with early DCM had higher concentration
of hemoglobin, however, levels of CK-MB, troponin, hs-
CRP, and NT-proBNP were similar. Both groups were on
optimal HF pharmacotherapy. However, as expected
patients with chronic DCM had significantly more ICDs
and CRTs implanted.
Comparison with controls
Comparison of serum ECM fibrosis parameters between
DCM and control group is depicted in the Table 2. Among
markers of collagen synthesis, only PIIINP was signifi-
cantly higher in DCM, whereas PICP, PINP, and PIIICP
were similar in DCM and controls. Furthermore, collagen-1
level was lower in DCM than in controls. CTGF levels
were higher in DCM but level of TGF-b1 did not differ
between DCM and controls. All indicators of increased
ECM turnover, such as MMP-2, MMP-9 and TIMP-1 were
significantly higher in DCM in comparison to control
group.
Comparison between early and chronic DCM
There were no differences in all measured serum markers of
ECM metabolism between patients with new-onset and
chronic DCM (Table 3). This means that synthesis of collagen
type I (markers-PICP, PINP, collagen-1) was not increased in
either early or chronic DCM, whereas synthesis of collagen
type III (marker-PIIINP) was homogenously increased
regardless of the duration of DCM. Moreover, increased ECM
turnover (high serum values of MMP-2, MMP-9, and TIMP-
1) was observed in both DCM groups. This also applies to the
fibrosis controlling factor, such as CTGF, which was
homogenously increased in both DCM cohorts. However,
level of TGF-b1, which was similar in DCM and controls, was
also evenly distributed in early and chronic DCM.
Table 1 Baseline characteristics of the study population
Parameter Group 1 (n = 35) Group 2 (n = 35) p value
Age (years) 48.5 ± 12 47.5 ± 12.3 0.73
Sex (male/female) 32 (91.4 %)/3 (8.6 %) 31 (88.6 %)/4 (11.4 %) 0.7
BMI (kg/m2) 27.7 ± 5 26.7 ± 5.7 0.4
NYHA class 2.49 ± 0.7 2.66 ± 0.76 0.33
Duration (months) 2.34 ± 1.4 46.3 ± 39.7 \0.001
LBBB (n, %) 10 (28.6 %) 8 (22.8 %) 0.3
LVESd/BSA (mm/m2) 28.3 ± 5.8 31.8 ± 7.9 0.04
LVEDd/BSA (mm/m2) 34.2 ± 5.3 37.1 ± 8.2 0.08
LVESvol/BSA (ml/m2) 91.9 ± 40.7 100.3 ± 56.2 0.48
LVEDvol/BSA (ml/m2) 122.7 ± 55.2 130.7 ± 64.5 0.59
EF (%) 24.5 ± 6.7 24.3 ± 8 0.91
E/E’ (average sep ? lat) 21.3 ± 12.6 20.5 ± 10.5 0.78
ECM fibrosis (n, %) 7 (20 %) 17 (48.6 %) 0.01
PA mean (mmHg) 22.6 ± 10.1 23.6 ± 11.7 0.69
pH (n, %) 11 (33.3 %) 16 (45.7 %) 0.3
VO2peak (ml/kg/min) 18.3 ± 6.5 15.5 ± 5.7 0.14
Hb (g/dl) 14.54 ± 1.38 13.46 ± 1.74 0.006
CK-MB (U/l) 11 (8–28) 12 (8–29) 0.08
hs-troponin T (ng/ml) 0.0197 ± 0.0123 0.0251 ± 0.0223 0.2
hs-CRP (mg/dl) 4.22 (0.15–141) 1.89 (0.17–96) 0.18
NT-proBNP (pg/ml) 1505 (69–27,012) 2088.5 (73–33,530) 0.36
Beta-blocker (n, %) 34 (97 %) 35 (100 %) 0.3
ACE-I (n, %) 34 (97 %) 32 (91.5 %) 0.3
ARB (n, %) 1 (3 %) 1 (3 %) 1
MRA (n, %) 33 (94 %) 33 (94 %) 1
Furosemide (n, %) 18 (51.4 %) 24 (68.6 %) 0.14
CRT/ICD (n, %) 9 (25.7 %) 18 (51.4 %) 0.03
Data are presented as median (range), as mean ± SD or n (%)
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Comparison between fibrosis positive and negative
DCM
We compared serum fibrosis parameters in patients with and
without ECM fibrosis (Table 4). It turned out that all mea-
sured fibrosis markers were at the similar level in both groups.
Furthermore, based on the duration of DCM and presence of
fibrosis, patients were divided into four groups: new-onset
DCM without (n = 28) and with (n = 7) fibrosis and chronic
DCM without (n = 18) and with (n = 17) fibrosis (Table 5).
Similarly, no differences were observed in serum parameters
of fibrosis between all four analyzed groups.
No correlations between serum fibrosis markers
and ECM fibrosis
Fibrosis was correlated only with the duration of DCM
(r = 0.23, p\ 0.05). However, not a single serum
marker of fibrosis correlated with ECM fibrosis. Fur-
thermore, fibrosis was not correlated with LV wall
thickness, diameters, and volumes as well as EF, blood
markers of myocardial necrosis (CK, CK-MB, troponin),
marker of inflammation (hs-CRP) or myocardial strain
(NT-proBNP).
Probability of fibrosis
Finally, we verified whether there is an impact of serum
markers of fibrosis on the probability of the ECM
fibrosis (Table 6). Three models were constructed:
unadjusted model (1), model with adjustment to the
disease duration (2) and model with adjustments to the
disease duration, age, sex and BMI (3). However, neither
unadjusted nor adjusted models predicted the probability
of ECM fibrosis.
Table 2 Serum values of ECM fibrosis parameters in DCM patients
Parameter DCM (n = 70) Control (n = 20) p value
Age (years) 48.04 ± 12.1 35.8 ± 7.9 \0.001
LVEDd (mm) 71.4 ± 11.5 49.3 ± 3.4 \0.001
EF (%) 24.4 ± 7.4 63.8 ± 4.7 \0.001
PICP (ng/ml) 0.17 (0.06–0.46) 0.23 (0.06–0.32) 0.56
PINP (pg/ml) 129.9 (25.2–1050.2) 129.9 (75.6–448.1) 0.89
PIIICP (pg/ml) 211.8 (70.3–1165.1) 187.2 (88.1–390.3) 0.47
PIIINP (ng/ml) 4.41 (2.17–6.08) 3.32 (1.69–5.02) 0.001
Col-1 (pg/ml) 57.7 (23.1–233.4) 159.4 (31.2–512.9) 0.001
TGF-b1 (ng/ml) 2.26 (0.65–6.97) 2.22 (0.97–4.74) 0.81
CTGF (ng/ml) 3.82 (0.48–23.87) 2.37 (0.51–25.32) 0.01
MMP-2 (ng/ml) 6.06 (2.72–14.8) 4.43 (2.27–7.4) 0.001
MMP-9 (ng/ml) 1.98 (0.28–9.25) 1.01 (0.29–3.59) 0.002
TIMP-1 (ng/ml) 15.29 (1.8–36.17) 2.61 (1.65–24.09) 0.004
Data are presented as median (range)
Table 3 Comparison of the serum ECM fibrosis parameters between early and chronic DCM
Parameter Group 1 (n = 35) Group 2 (n = 35) p value
PICP (ng/ml) 0.18 (0.06–0.29) 0.15 (0.06–0.46) 0.52
PINP (pg/ml) 132.1 (31.2–625.2) 129.9 (25.2–1050.2) 0.43
PIIICP (ng/ml) 209.9 (77.2–1165.1) 213.7 (70.3–717.7) 0.79
PIIINP (ng/ml) 4.3 (2.4–5.37) 4.4 (2.17–6.08) 0.51
Col-1 (pg/ml) 67.44 (23.1–206.5) 55.96 (31.2–233.4) 0.42
TGF-b1 (pg/ml) 2.21 (1.21–6.31) 2.24 (0.65–6.9) 0.86
CTGF (ng/ml) 3.3 (0.48–12.4) 4.99 (0.65–23.9) 0.14
MMP-2 (ng/ml) 5.99 (2.7–12.89) 6.14 (2.97–14.83) 0.58
MMP-9 (ng/ml) 1.94 (0.28–9.25) 1.99 (0.29–6.96) 0.89
TIMP-1 (ng/ml) 15.79 (1.8–35.16) 14.88 (2.4–36.17) 0.74
Data are presented as median (range)
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Table 4 Comparison of the serum ECM fibrosis parameters between ECM fibrosis positive and negative DCM patients
Parameter ECM fibrosis negative (n = 46, 65.7 %) ECM fibrosis positive (n = 24, 34.3 %) p value
PICP (ng/ml) 0.18 (0.06–0.46) 0.16 (0.06–0.44) 0.88
PINP (pg/ml) 129.92 (25.2–625.2) 128.75 (31.2–1050.2) 0.7
PIIICP (ng/ml) 241.1 (83.51–165.1) 151.84 (70.3–717.7) 0.12
PIIINP (ng/ml) 4.41 (2.17–5.78) 4.21 (2.9–6.08) 0.94
Col-1 (pg/ml) 56.89 (23.1–206.5) 58.69 (27.9–233.4) 0.96
TGF-b1 (pg/ml) 2.18 (0.65–6.97) 2.24 (1.21–5.89) 0.32
CTGF (ng/ml) 3.39 (0.48–12.4) 4.3 (0.65–23.87) 0.44
MMP-2 (ng/ml) 6.06 (2.7–14.8) 6.06 (2.97–8.43) 0.99
MMP-9 (pg/ml) 2.03 (0.28–9.25) 1.59 (0.29–6.96) 0.45
TIMP-1 (pg/ml) 14.88 (1.8–35.16) 15.31 (2.1–36.17) 0.83
Data are presented as median (range)
Table 5 Comparison of serum markers of fibrosis between four groups of DCM patients, divided according to the duration of disease and
fibrosis status
Parameter Early DCM without
fibrosis (n = 28)
Early DCM with
fibrosis (n = 7)
Chronic DCM without
fibrosis (n = 18)
Chronic DCM with
fibrosis (n = 17)
p value
PICP (ng/ml) 0.19 (0.06–0.29) 0.15 (0.06–0.28) 0.15 (0.06–0.46) 0.17 (0.08–0.44) 0.89
PINP (pg/ml) 138.7 (44.7–625.2) 116.2 (31.2–221) 128.8 (25.2–594.9) 134.3 (48.1–1050.2) 0.56
PIIICP (ng/ml) 205.6 (83.5–1165) 209.9 (77.2–648) 258.5 (107.5–627.7) 147.5 (70.3–717.7) 0.49
PIIINP (ng/ml) 4.4 (2.4–5.4) 3.9 (3.1–5.01) 4.42 (2.17–5.78) 4.49 (2.92–6.08) 0.75
Col-1 (pg/ml) 72.3 (23.1–206.5) 57.7 (27.9–107.6) 47.8 (31.2–129.8) 59.7 (31.2–233.4) 0.48
TGF-b1 (ng/ml) 2.2 (1.36–6.31) 2.15 (1.2–5.88) 1.85 (0.65–6.97) 2.24 (1.49–5.73) 0.66
CTGF (ng/ml) 3.39 (0.48–12.4) 2.92 (1.2–11.98) 4 (1.44–11.75) 5.15 (0.65–23.8) 0.38
MMP-2 (ng/ml) 5.99 (2.7–12.9) 6.83 (4.56–7.24) 6.21 (3.5–14.8) 5.99 (2.97–8.43) 0.83
MMP-9 (ng/ml) 2.1 (0.28–9.24) 1.34 (0.34–5.9) 2.01 (0.58–5.77) 1.72 (0.29–6.9) 0.86
TIMP-1 (ng/ml) 16.3 (1.8–35.2) 15.3 (2.1–30.5) 14.39 (2.4–29.8) 15.9 (4.05–36.17) 0.96
Data are presented as median (range)
Table 6 Models to predict the probability of ECM fibrosis
Parameter Model 1 Model 2 Model 3
OR 95 % CI p OR 95 % CI p OR 95 % CI p
PICP (ng/ml) 1.6 0.005 [100 0.87 0.99 0.003 [100 0.99 8.12 0.009 [100 0.54
PINP (pg/ml) 1.001 0.998 1.003 0.98 0.997 0.996 1.0031 0.88 0.999 0.996 1.003 0.72
PIIICP (ng/ml) 0.999 0.996 1.001 0.302 0.999 0.996 1.001 0.348 0.999 0.996 1.002 0.38
PIIINP (ng/ml) 1.001 0.999 1.005 0.9 0.998 0.999 1.004 0.76 0.998 0.999 1.0004 0.49
Col-1 (pg/ml) 1.002 0.99 1.01 0.65 1.001 0.99 1.01 0.85 0.99 0.98 1.01 0.72
TGF1-beta (pg/ml) 1.001 0.999 1.005 0.45 1.0024 0.9981 1.0068 0.27 1.0033 0.999 1.0081 0.17
CTGF (ng/ml) 1.072 0.937 1.227 0.309 1.057 0.922 1.211 0.429 1.067 0.929 1.226 0.35
MMP-2 (ng/ml) 0.925 0.731 1.171 0.517 0.878 0.684 1.128 0.309 0.861 0.663 1.119 0.26
MMP-9 (pg/ml) 0.9991 0.999 1.0002 0.525 0.9998 0.9995 1.0002 0.454 0.9999 0.999 1.0002 0.5
TIMP-1 (pg/ml) 1.0001 0.999 1.0006 0.67 1 0.9994 1.0005 0.922 0.9999 0.993 1.0005 0.7
Data are presented as median (range)
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123
Discussion
The main findings of the study are as follows: (1) blood
marker of collagen type III synthesis was found to be
increased in DCM whereas indices of collagen type I
synthesis were not different compared to controls (2) all
measured serum markers of ECM fibrosis did not differ
between new-onset and chronic DCM as well as fibrosis
positive and negative patients (3) none of the serum
markers of fibrosis correlated or predicted the probability
of ECM fibrosis.
ECM fibrosis
The ECM undergoes fibrotic remodeling in the majority of
various cardiac diseases and also as a function of age,
resulting in a decreased myocardial compliance and altered
functionality. Myocardial fibrosis present as two main
patterns: reactive (or diffuse) fibrosis describes the
expansion of collagen fibers without a significant loss of
myocytes, and replacement (or reparative) fibrosis occurs
when collagen is deposited in places of necrotic/apoptotic
myocytes. Thus, reactive fibrosis is typically observed in
DCM, hypertrophic cardiomyopathy or in the aging heart,
whereas replacement fibrosis is commonly present after
myocardial infarction, myocarditis or sarcoidosis [14].
Although in the broad terms ECM fibrosis can be divided
into two aforementioned groups, nevertheless, specific
patho-mechanisms leading to fibrosis greatly differ
between various diseases [15]. Data on the fibrosis process
in DCM come from few and small studies, usually from
single, highly specialized centers. In a landmark study,
Pauschinger et al. observed greater increase of collagen
type I than type III deposition, with an overall increase in
the collagen type I to III ratio in DCM [16]. Some subse-
quent studies confirmed the initial observation on the
altered ratio of collagen type I and III in the myocardium.
Increased myocardial deposition of collagen type I and III
implies increased synthesis and high concentrations of
metabolic by-products that are released into circulation.
Measuring those blood molecules may help to understand
the ECM remodeling.
Collagen metabolism
As ECM fibrosis is an ongoing process in DCM, it is
expected to observe persistently high blood levels of
collagen pro-peptides. However, discordant findings on
the collagen metabolism parameters were reported thor-
ough the studies. So far, among numerous studied
circulating molecules, only two collagen-derived serum
peptides, such as PICP and PIIINP have been shown to
be clearly associated with myocardial fibrosis [7, 17, 18].
Querejeta et al. found increased blood marker of colla-
gen type I synthesis (PICP) in HF patients of
hypertensive origin [17]. Similarly, Izawa et al. observed
association between PICP and LV fibrosis in spirono-
lactone treated DCM patients [18]. In line with this,
Klappacher and colleagues showed association between
PIIINP and ECM fibrosis in patients with ischemic and
dilated cardiomyopathy [7]. On the other hand, Timonen
et al. reported that serum levels of markers of collagen
type I synthesis (PICP and PINP) were actually lower in
patients than in controls, whereas markers of collagen
type III synthesis (PIIICP and PIIINP) were higher in
DCM patients [19]. Slightly different approach to study
ECM metabolism was proposed by Sezen et al. who
measured serum prolidase activity, an important
exopeptidase involved in collagen turnover, and found
lower blood level of prolidase in DCM than in healthy
controls, which actually suggested decreased collagen
turnover in DCM [20]. In our study, we observed that
serum markers of collagen type I synthesis (PICP and
PINP) did not differ between DCM and controls but
PIIINP was significantly higher in DCM, which may
suggest increased collagen type III synthesis. However,
this issue seems to be more complex. Since, PICP is
formed in a 1:1 stoichiometric ratio to the collagen type
I molecule formed, the pro-peptide concentrations in
blood are direct indicators of ongoing collagen type I
synthesis [4, 5]. Therefore, observed lack of differences
of PICP serum concentrations between DCM and con-
trols clearly suggest low intensity of collagen type I
synthesis. What is even more interesting, is comparable
intensity of collagen type I synthesis in new-onset and
chronic DCM, as well as in fibrosis positive and negative
patients, as serum concentrations of PICP and PINP were
not different between groups. The formation of collagen
type III is slightly more complex as the cleavage at the
amino-terminus proceeds at slower rate and, thus, par-
tially processed procollagen molecules (p-N collagen
type III molecules) can be found on the surface of col-
lagen type III fibers. Although, blood concentration of
PIIINP was found to be related to ECM fibrosis, it
should be admitted that PIIINP concentrations in blood
are not direct indicators of ongoing collagen type III
synthesis [4, 5, 8]. Bearing this in mind, we found
increased concentrations of PIIINP (but not PIIICP,
which is less studied) in DCM in comparison to the
controls but no differences between new-onset and
chronic DCM and fibrosis positive and negative patients.
Therefore, none of the studied serum markers of ECM
metabolism helped to distinguish between new-onset and
chronic DCM or fibrosis positive and negative DCM.
Consequently, none of serum makers of collagen syn-
thesis correlated or predicted the probability of fibrosis.
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ECM fibrosis controlling factors
The activation of renin-angiotensin-aldosterone system is a
major determinant of fibroblast activation and collagen
deposition, with TGFb and CTGF acting as the sequential
downstream signal mediators [1–3]. The role of TGFb and
CTGF in the pathogenesis of cardiac remodeling and HF
has been extensively studied in the animal models [21].
However, performed studies in humans provided conflict-
ing results. Increased expression of TGFb and CTGF in
hearts and in blood from patients with DCM, hypertrophic
cardiomyopathy, and aortic stenosis has been confirmed
but their relevance to ECM fibrosis remains unproven. In
one study plasma TGFb levels were found to be correlated
with the LV myocardial expression of collagen type I
mRNA in patients with severe aortic stenosis but no cor-
relation was observed with invasively determined LV
fibrosis [22]. Furthermore, it has been reported that plasma
TGFb was higher in controls than in patients with DCM
[23]. This observation is in line with our results that plasma
levels of TGFb did not differ between DCM patients and
the control subjects. Moreover, neither TGFb nor CTGF
differed between new-onset and chronic DCM or patients
with and without fibrosis.
Matrix metalloproteinases and tissue inhibitor
(MMP/TIMP) system
In healthy conditions, the MMP/TIMP system remains in a
dynamic balance, however, in pathological conditions, there
is an over-expression of MMPs and down-regulation of
TIMPs [24]. Numerous MMPs and TIMPs were found to be
associated with long-term prognosis in HF and DCM but
associations with cardiac fibrosis, although plausible from
the pathologic point of view, have not been clearly demon-
strated [25]. Sivakumar et al. found that myocardial content
of MMP-2, MMP-9, TIMP-1, and TIMP-2 were significantly
increased in DCM hearts compared to non-failing hearts
[26]. Completely opposite data were provided by Batlle et al.
who analyzed LV biopsies in advanced DCM and control
heart donors and did not find any differences in the expres-
sion levels of MMP-1, MMP-2, MMP-3, and TIMP-1
between pathological hearts compared to control hearts [27].
Moreover, expression levels of MMP-9 were even down-
regulated in diseased heart compared to controls. Only
MMP-2 expression levels weakly correlated with fibrosis
[27]. In line with this, Lopez and colleagues did not observe
any correlations between serum levels of MMP-1, TIMP-1 or
their ratio and invasively assessed fibrosis in HF patients
[28]. In our study, we also did not find correlations between
MMPs and TIMP-1 and cardiac fibrosis but we observed
significantly higher values of MMP-2, MMP-9, and TIMP-1
in DCM than in controls, this suggests an ongoing ECM
remodeling and increased collagen turnover in DCM.
Interestingly, Picard et al. reported highest myocardial
expression of MMP-1 and TIMP-1 in DCM patients with
mildly dilated LV in comparison to those patients with either
no LV dilatation or severe LV dilatation [29]. They con-
cluded that the dynamics of LV dilatation and collagen
turnover is highest in the early phases of cardiac remodeling.
Although we did not measure myocardial expression of
MMPs or TIMP, we found completely no differences in
serum concentrations of MMP-2, MMP-9 and TIMP-1 in
DCM patients regardless of duration of the disease or pres-
ence/absence of ECM fibrosis.
Conclusions
We studied serum markers of fibrosis from various groups
and points of action, including markers of collagen syn-
thesis (PICP, PINP, PIIICP, PIIINP, collagen-1), fibrosis
controlling factors (TGFb and CTGF), and enzymes
degrading collagen fibers (MMP-2, MMP-9, and TIMP-1)
in homogenous DCM cohort with significant LV remod-
eling and LV systolic dysfunction. Based on our results, we
speculate that once ECM remodeling in DCM starts
(probably at early stages), its course and dynamics is
homogenously increased in both new-onset or chronic
DCM and as well as in fibrosis positive and negative DCM.
Serum markers of collagen synthesis do not seem to be
useful in the differentiation of new and chronic DCM or
patients with or without fibrosis. Furthermore, serum
markers of ECM metabolism were found not to useful for
the prediction of myocardial fibrosis in DCM.
Study limitations
This study has several limitations that should be acknowl-
edged. The control group is significantly younger than the
study group. However, the recruitment period of DCM
patients lasted 12 months so the age- and sex-matched
control group was found very difficult and impractical.
Although we precisely defined the term—duration of
symptoms (‘‘Methods’’ section), that was used to differen-
tiate patients into early and late DCM, we cannot completely
rule out that some patients defined as new-onset DCM could
have had milder HF symptoms that were unreported and not
investigated. Because of the patchy distribution of myocar-
dial fibrosis, the greatest potential limitation to
endomyocardial biopsy evaluation is sampling error.
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